International journal of urology : official journal of the Japanese Urological Association · 2025
Preliminary Evaluation of Nontransecting Anastomotic Urethroplasty for Pelvic Fracture Urethral Injury: Insights From a Comparison With Excision and Primary Anastomosis.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Katsuta Jumpei, Horiguchi Akio, Shinchi Masayuki, Ojima Kenichiro, Takekawa Kazuki, Furukawa Yoshiyuki, Minami Takahiro, Suzuki Sadayoshi, Masumoto Hakaru, Watanabe Daisuke, Ito Keiichi
Аннотация
OBJECTIVES: To evaluate the feasibility and surgical and patient-reported outcomes of nontransecting anastomotic urethroplasty (NTAU) for male patients with pelvic fracture urethral injury (PFUI) compared with excision and primary anastomosis (EPA), the current mainstay surgical approach.
METHODS: This retrospective study analyzed 233 male PFUI patients treated with EPA (n = 223) or NTAU (n = 10) from 2008 to 2024 by a single surgeon (AH). NTAU involves preserving urethral continuity and maintaining bilateral bulbar artery integrity while excising scar tissue and achieving tension-free urethral anastomosis. Anatomical success was defined as the ability to pass a 17Fr flexible cystourethroscope through the anastomotic site without resistance and no need for additional treatments. Postoperative functional outcomes were assessed using validated patient-reported measures, including the LUTS-specific quality-of-life (QOL) questionnaire, the Sexual Health Inventory for Men (SHIM), and the EuroQol Visual Analog Scale (EQ-VAS).
RESULTS: Although the median follow-up period was significantly shorter for NTAU (12 vs. 69 months, p < 0.0001), the anatomical success rate was 100% for NTAU and 94.6% for EPA, with no significant difference between the groups (p = 0.45). No significant differences were observed in the perioperative complication rate (p = 0.54). The changes in LUTS-QOL, SHIM, and EQ-VAS scores from preoperative to postoperative assessments were also comparable, indicating similar patient-reported outcome improvements in both groups (p = 0.71, p = 0.16, p = 0.92, respectively).
CONCLUSION: NTAU has the potential to achieve surgical and patient-reported outcomes comparable to EPA. Further studies are warranted to validate its long-term benefits and define its optimal indications.
METHODS: This retrospective study analyzed 233 male PFUI patients treated with EPA (n = 223) or NTAU (n = 10) from 2008 to 2024 by a single surgeon (AH). NTAU involves preserving urethral continuity and maintaining bilateral bulbar artery integrity while excising scar tissue and achieving tension-free urethral anastomosis. Anatomical success was defined as the ability to pass a 17Fr flexible cystourethroscope through the anastomotic site without resistance and no need for additional treatments. Postoperative functional outcomes were assessed using validated patient-reported measures, including the LUTS-specific quality-of-life (QOL) questionnaire, the Sexual Health Inventory for Men (SHIM), and the EuroQol Visual Analog Scale (EQ-VAS).
RESULTS: Although the median follow-up period was significantly shorter for NTAU (12 vs. 69 months, p < 0.0001), the anatomical success rate was 100% for NTAU and 94.6% for EPA, with no significant difference between the groups (p = 0.45). No significant differences were observed in the perioperative complication rate (p = 0.54). The changes in LUTS-QOL, SHIM, and EQ-VAS scores from preoperative to postoperative assessments were also comparable, indicating similar patient-reported outcome improvements in both groups (p = 0.71, p = 0.16, p = 0.92, respectively).
CONCLUSION: NTAU has the potential to achieve surgical and patient-reported outcomes comparable to EPA. Further studies are warranted to validate its long-term benefits and define its optimal indications.